Insight

Jan 23, 2025, 06:31

Highlights from DESTINY-Breast06 trial presented at the 17th BGICC by Giuseppe Curigliano

Prof. Giuseppe Curigliano, President-Elect of ESMO, shared groundbreaking results from the DESTINY-Breast06 trial, showcasing the efficacy of trastuzumab deruxtecan (T-DXd) in patients with HR+, HER2-low or HER2-ultralow metastatic breast cancer (mBC).

DESTINY-Breast06

Key Findings:

Improved Response Rates and Duration:

Confirmed ORR (BICR): 57.8% in HER2-low and ultralow patients treated with T-DXd, significantly outperforming chemotherapy.
Median Duration of Response (DOR):
11.1 months for <6-month TTP on 1L ET + CDK4/6i
13.7 months for 6-12 month TTP
16.7 months for >12-month TTP
Demonstrated efficacy in both primary and secondary endocrine resistance settings.

HER2 Reassessment Matters:

94% of patients locally scored as HER2-low were confirmed as HER2-low or HER2-ultralow centrally, making them eligible for the trial.
Reassessing HER2 IHC 0 patients is critical, as 64% were centrally identified as HER2-low (24%) or HER2-ultralow (40%).

Safety Profile Remains Consistent:

Gastrointestinal and hematologic toxicities were in line with previous data.
Incidence of ILD (11%) highlights the importance of timely diagnosis and intervention.

Highlights from DESTINY-Breast06 trial presented at the 17th BGICC by Giuseppe Curigliano

Why This Matters:

The results from DESTINY-Breast06 reinforce the clinical potential of T-DXd in redefining treatment for HER2-low and ultralow populations, particularly for HR+ mBC patients who have historically had limited options. Increased awareness of HER2-low expression is crucial for identifying eligible patients and optimizing outcomes.

Future Directions:

As the HER2-low paradigm evolves, reassessment protocols and greater collaboration between local and central labs will play a pivotal role in ensuring access to innovative therapies like T-DXd.

Let’s continue the conversation about advancing treatments for breast cancer and improving patient outcomes!

DESTINY-Breast06